Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of March 14, 2025 • 7:31 AM ET

Date/Time Source News Release
02/03/2025 08:00 AM EST GlobeNewswire Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
01/13/2025 08:00 AM EST GlobeNewswire Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement
06/17/2024 08:00 AM EDT GlobeNewswire Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
06/12/2024 08:00 AM EDT GlobeNewswire Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
03/22/2024 04:05 PM EDT GlobeNewswire Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
01/16/2024 08:00 AM EST GlobeNewswire Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
01/03/2024 08:30 AM EST GlobeNewswire Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
11/07/2023 08:30 AM EST GlobeNewswire Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
08/10/2023 04:05 PM EDT GlobeNewswire Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
08/08/2023 04:05 PM EDT GlobeNewswire Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
Page

Additional News

As of March 14, 2025 • 7:31 AM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.